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J. Stuart Elborn
President, European Cystic Fibrosis Society
This supplement of the Journal of Cystic Fibrosis sum-
marises some of the outputs from a wide range of work-
packages delivered in the European Commission Framework
6-funded programme of EuroCareCF. This body of work
summarises a huge effort undertaken by a wide range of
people involved in cystic ﬁbrosis (CF) across Europe with
helpful collaborations from colleagues from other continents.
This programme has made a huge contribution to establishing
a range of very signiﬁcant infrastructures within the CF
community in Europe and provides a really solid foundation
for us to continue in our quest to improve the quality of care
for patients with CF and ﬁnd ever more effective treatments to
reduce the morbidity and improve survival resulting from this
terrible disease.
Firstly, I want to acknowledge the leadership given to this
programme of work by David Sheppard ably supported by
Margarida Amaral. Their unfailing efforts have ensured the
delivery of the workpackages and the CF community is very
grateful for all the sacriﬁce and effort required to ensure the
successful completion of the programme. They were assisted
by workpackage leaders from a range of disciplines who have
provided extensive reports in this supplement on a wide range
of activities undertaken in the programme. The included re-
ports range from important guidelines on clinical care through
standardisation and development of outcome measures and
endpoints for clinical trials to considerations of the ethical
issues in the conduct of clinical trials. The important role of
model systems and the development of new therapeutics in an
academic and industry context has also been widely explored.
The centrepiece of the programme was the demographic iden-
tiﬁcation of CF patients in Europe which has led to a strong
basis for the development of an ongoing European CF registry
in collaboration with many of the already established national
registries. This work has already had an impact identifying the
reduced survival in Eastern European countries and challeng-
ing us as a safe community in Europe to address important
issues relating to the delivery of CF care.
The work of EuroCareCF was funded for three years
through Framework 6 and we are very grateful for the support
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of the European Commission through this funding mecha-
nism. The work of EuroCareCF did not ﬁnish with the funding
and continues from the excellent work done in the various
workpackages. Many of the workpackages have resulted in
productive collaborations and will result in further important
outputs. From the efforts of the clinical trials group under the
leadership of Kris De Boeck, we have subsequently estab-
lished the European Cystic Fibrosis Society (ECFS) Clinical
Trials Network (ECFS-CTN) as collaboration between the
ECFS and national patient associations. This represents a key
collaboration across Europe and is already an international
partner with the US CF Foundation Therapeutic Develop-
ment Network and pharmaceutical companies developing new
therapies for CF. Clinical research and clinical trials can
now be undertaken in Europe in a co-ordinated and timely
manner. Secondly, the European CF Registry has been able to
engage with countries that currently do not have registries and
ongoing work will help establish registries in further countries
across Europe. In addition, very effective collaborations in
basic science have been established and through the support
of EuroCareCF, the ECFS has undertaken to run a basic
science meeting annually to bring together a wide range of
disciplines to scope the challenges in understanding mecha-
nisms of disease in CF and ensuring that direction is given to
the development of appropriate therapeutics.
To continue to improve the care of patients with CF and
to develop ever more effective therapies and care delivery
requires the development of further international collabora-
tions. The EuroCareCF Programme has catalysed the effort in
Europe towards these goals and facilitated the development
of a secure and focussed infrastructure which will allow
more effective collaboration with colleagues in the USA and
Canada, Australasia and South America to develop worldwide
programmes of care and to ensure that as many patients as
possible with CF have an opportunity to participate in clinical
trials and ultimately to receive effective therapy.
Many thanks to all who have contributed to this important
programme. This supplement is, in addition to being an
effective working document in a wide range of areas, also a
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testimony to the commitment of scientists, clinicians, national
organisations and people with CF to ensure we develop
new and effective therapies. EuroCareCF demonstrates the
powerful impact of collaboration in Europe.
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